drugset / Trial / NCT00136409
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Phase 2
Completed
34 enrolled
Dana-Farber Cancer Institute
Brigham and Women's Hospital · collabMassachusetts General Hospital · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effects (good and bad) of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia.
Timeline
- Start
- 2002-05
- Primary completion
- 2005-08
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | Oral |